Skip to content
Home/Companies/Biotech/ApoGlyx

ApoGlyx

Biotech·Sweden·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns ApoGlyx?

ApoGlyx is a Swedish Biotech company, currently owned by Almi Invest since 2021.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Almi Invest
Investor
Almi Invest
Almi Invest (Regional funds) · 2009 · VC

Key facts

HQSweden
SectorBiotech
StatusActive

More from Almi Invest (Regional funds)

Other portfolio companies in the same fund.

Cellevate
Active
BiotechSweden· 2026
CubaseBio
Active
BiotechSweden· 2026
DAJE Prevent
Active
MedTechSweden· 2026
Permitify
Active
SaaSSweden· 2026
Radar Reticence
Active
SoftwareSweden· 2026
Rivus
Active
SoftwareSweden· 2026

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns ApoGlyx?

ApoGlyx is currently owned by Almi Invest, through Almi Invest (Regional funds), since 2021.

When did Almi Invest acquire ApoGlyx?

Almi Invest acquired ApoGlyx in 2021.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue